ZyVersa Therapeutics, Inc.
corporate_fare Company Profile
ZyVersa Therapeutics, Inc. (OTC:ZVSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for ZVSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-13, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for ZVSA spans 10-K, 8-K.
Recent high-impact activity:
- ZyVersa Therapeutics Reports $0 Revenue, $1.79M Net Loss in Q1 Amid Ongoing Liquidity Concerns
- ZyVersa Faces Going Concern Doubt, Nasdaq Delisting, and $18.6M R&D Impairment
- ZyVersa Therapeutics Secures $1M in Highly Dilutive Convertible Note and Warrant Offering
Short Interest & Short Volume
14.63 days to coverFINRA reported short interest of 141,630 shares in ZVSA as of the September 15, 2026 settlement, unchanged from the prior period — about 14.6 days to cover at its recent average daily volume. On October 1, 2026, 0.2% of ZVSA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.